The study’s findings offer a novel perspective on norepinephrine reuptake inhibitors’ impact on “upper airway stability during sleep and are significant to guide future pharmacotherapy development for OSA,” according to the authors. Additionally, the findings offer individuals who are unable to tolerate modern therapies, such as continuous positive airway pressure (CPAP) equipment, wider alternatives when seeking therapy for OSA.